IP Group completes partial realisation in ONT

IP Group completes c.£21m partial realisation in Oxford Nanopore

IP Group plc ("IP Group" or the "Group") (LSE: IPO), which invests in breakthrough science and technology companies with the potential to create a better future for all, announces that it has completed a partial realisation of its holding in Oxford Nanopore Technologies plc ("Oxford Nanopore" or the "Company").

IP Group has sold 10,000,000 ordinary shares in Oxford Nanopore (the "Sale"), generating gross proceeds of c.£21m. Following completion of the Sale, IP Group remains one of Oxford Nanopore's largest shareholders, holding 70,775,255 ordinary shares, representing 7.23% of the company, and valued at £151.5m at the current market price. In addition, funds managed by IP Group continue to hold approximately 11.8 million Oxford Nanopore shares. The Sale proceeds further enhance IP Group's financial flexibility and support the disciplined allocation of capital across the portfolio and broader Group priorities.

Greg Smith, Chief Executive of IP Group, said: "Oxford Nanopore has been one of the standout successes within our portfolio and we remain strong supporters of the company, its management team and its long-term prospects. This transaction represents an appropriate partial realisation of our holding, demonstrating our ability to realise value from maturing portfolio companies while preserving meaningful exposure to future upside. We retain a significant investment in Oxford Nanopore, continue to see substantial long-term potential in the business and look forward to supporting its future development as a major shareholder."

IP Group has entered into a 90-day lock-in undertaking with Joh. Berenberg, Gossler & Co ("Berenberg") with respect to its retained direct holding of 70,775,255 ordinary shares in the Company, subject to certain customary exceptions and/or waiver by Berenberg.

For more information, please contact:

Notes for editors

About IP Group

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science and technology investor, we develop and support some of the world's most exciting businesses in healthtech, deeptech and cleantech. Including through Parkwalk, the UK's largest growth EIS fund manager, we back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, Hinge Health, Featurespace, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

For more information, please visit our website at www.ipgroupplc.com.